September 2018 Victoria has world-leading competitive advantages in the health industry, which encompasses health and medical research, biotechnology, medical technology, pharmaceuticals, digital health, healthcare delivery, global health and health services. Victoria’s healthcare sector contributes to more than $30…
Immutep Limited is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc., to evaluate the combination of Immutep’s lead immunotherapy product candidate eftilagimod alpha…
Fast-tracking innovative technologies through early proof-of-concept and feasibility stages is a key aim of Burnet Institute’s new initiative, the Quick Development of Solutions Lab (qDOS Lab). Nurturing technologies through key early-stage development phases by adopting a market led approach is a primary focus…
Australia’s premier early stage MedTech challenge is seeking Australia’s aspiring next generation MedTech entrepreneurs and innovators. Now in its fifth and largest year, MedTech’s Got Talent has opened its 2018 application round. Top teams win a share in over…
The R&D tax incentive program is the Government’s largest program designed to support business innovation. It has been reviewed multiple times, with each review concluding it provides significant benefits to the Australian economy, far beyond the cost. AusIndustry…
Last Friday, BioMelbourne Network hosted the Molecules, Medicines and Markets Biotech Development Lab. One of our volunteers, Emma Wanicek, wrote the following summary of the event. Emma is a Research Assistant in the HIV Neuropathogenesis Laboratory in the Chronic Infectious and…
Sienna Cancer Diagnostics Ltd has appointed Shaanxi GaoYuan In Vitro Diagnostic Reagents Co. (“GaoYuan”) as the Company’s exclusive distribution partner for mainland China. The distribution agreement for mainland China is a milestone in Sienna’s geographical expansion strategy. The agreement…
Immutep today reports in its operational update that the final patient in Part B of the ongoing TACTI-mel Phase I clinical trial in Australia has now been recruited and is receiving treatment. Patients will be treated for up…
August 2018 On behalf of the members, BioMelbourne Network has made a submission to Treasury regarding the proposed changes to the R&D Tax Incentive. In terms of our overall consideration of the proposed changes to the R&D Tax…
BioCurate Pty Ltd has achieved an important milestone announcing investments in six early drug discovery projects from research groups at The University of Melbourne and Monash University. These projects represent the first tranche of investments for BioCurate: Dr…
As part of the Victorian Government’s Victoria Cancer Action Plan 2016-2020, five of the state’s most brilliant scientific minds will receive $1.5 million in grants to support their ground-breaking discoveries and medical breakthroughs in cancer research. The grants,…
Applications are now open for the Women in Leadership Development (WILD) Program. WILD is open to Victorian women in the science, technology, engineering and maths (STEM) sector. The program builds qualifications, skills and confidence to help women attain senior leadership…